In vivo effects of multiple cycles of recombinant interleukin-2 (IL2) on peripheral granulocyte-macrophage hematopoietic progenitors circulating in the blood of cancer patients

Tumori. 1991 Oct 31;77(5):420-2. doi: 10.1177/030089169107700509.

Abstract

The numbers of peripheral blood (PB) granulocyte-macrophage colony forming units (CFU-GM) were evaluated in five patients treated with multiple weekly cycles of recombinant interleukin-2 (IL2). A 4.5-12 fold increase in the number of CFU-GM was evident within 8 days after the beginning of the treatment. The maximal increase in the absolute numbers of CFU-GM/ml blood caused by the IL2 treatment, ranged from 14 to 57 times the baseline values and was reached after two or three cycles of IL2. IL2-activated PBMC, added in vitro to the PBMC of a normal donor did not modify the number of CFU-GM present in the donor PBMC. CFU-GM were also recovered from frozen samples of in vivo IL2-activated PBMC.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Drug Administration Schedule
  • Granulocytes / drug effects*
  • Hematopoietic Stem Cells / drug effects*
  • Humans
  • Interleukin-2 / administration & dosage
  • Interleukin-2 / pharmacology*
  • Macrophages / drug effects*
  • Neoplasms / blood*
  • Recombinant Proteins / administration & dosage
  • Recombinant Proteins / pharmacology

Substances

  • Interleukin-2
  • Recombinant Proteins